Influenzalike Illness Among Homeless Persons

To the Editor: We report rates of inﬂuenzalike illness (ILI) and inﬂuenza vaccination among homeless persons at 3 shelter clinics in New York City examined from 1997 through 2004. Little is understood regarding the prevalence and transmission of inﬂuenza among the homeless (1). Further inquiry on this topic is timely because of concern over a possible inﬂuenza pandemic, because of US goals to increase vaccination rates among high-risk groups (2), and because of the potential threat to persons who live and work in shelters. Homeless shelters are paradigmatic congregate settings and thus likely sites for transmission of airborne pathogens such as inﬂuenza viruses and tubercle bacilli, shown in part by numerous tuberculosis outbreaks among the homeless (3).

Homeless persons experience high rates of pneumonia (4) and related death (5,6). This outcome indicates that the homeless also have high rates of inﬂuenza because pneumonia is a common complication of inﬂuenza. Depending upon patient’s age and sex, death rates attributed to pneumonia or inﬂuenza among homeless adults ranged from 1.6 to 6.3 (95% conﬁdence interval 0.4–24.1) in one study (7). The New York City Departments of Health and Mental Hygiene and Homeless Services reported in December 2005 that 1% of hospitalizations and 3.4% of deaths of homeless adults in New York City from 2001 to 2003 were caused by inﬂuenza or pneumonia (8).

We analyzed 4,319 medical charts of persons who received medical services in 3 New York City homeless shelter clinics during inﬂuenza seasons (i.e., October 1 through May 30) from 1997 through 2004. This study was approved by the St. Vincent’s Hospital Research Committee and Institutional Review Board. This analysis identified 59 recorded cases of ILI, deﬁned as temperature ≥100°F (37.8°C) and cough, sore throat, or both (Table). ILI is accepted as an indicator of inﬂuenza by the Centers for Disease Control and Prevention and others (9).

The overall medical chart review also showed that less than one fourth of all persons examined and one third of those ≥65 years of age had evidence of inﬂuenza vaccination noted in their charts. Vaccinations are available from many sources, but those given at shelter clinics accounted for a large percentage, and vaccination rates varied widely by homeless shelter clinic site.

This study has some limitations. Because vaccinations are offered at numerous health centers, rates of vaccination based on the medical charts we studied may be underestimated. Moreover, since only those homeless persons at shelters who attended the medical clinic provided data, the findings cannot be used to make generalizations regarding ILI or inﬂuenza vaccination rates among the general population of the shelters. Nonetheless, these numbers can serve as a basis for more rigorous inquiry.

The implementation of an appropriate public health response is critical in maintaining the health of homeless persons. Controlling inﬂuenza transmission within shelters may beneﬁt the broader public in the same way that reducing the rates of tuberculosis among homeless persons is regarded as essential in preventing transmission to the general population.

The decision to receive an inﬂuenza vaccination is inﬂuenced by many factors. These factors include concern with related side effects, belief that the vaccine is not required, previous bad reactions, dislike of injections, and doubts about vaccine efﬁcacy (10). Understanding how these factors affect vaccination rates among the homeless would be valuable in planning healthcare interactions and quality improvements. Similarly, since the New York City Departments of Health and Mental Hygiene and Homeless Services recommend that inﬂuenza immunizations be provided to all sheltered homeless adults and shelter staff (8), further inquiry would help determine the risk-beneﬁt balance of such an approach.

Table. Cases of inﬂuenzalike illness (ILI) among homeless persons by inﬂuenza season, New York City, 1997–2004

| Season   | Shelter 1 | Shelter 2 | Shelter 3 | Total |
|----------|-----------|-----------|-----------|-------|
|          | No. cases | No. patients seen | % patients seen with ILI | No. cases | No. patients seen | % patients seen with ILI | No. cases | No. patients seen | % patients seen with ILI | No. cases | No. patients seen | % patients seen with ILI |
| 1997–98  | 5         | 284       | 1.8       | 3       | 221       | 1.4       | 3       | 202       | 1.5       | 11       | 707       | 1.6       |
| 1998–99  | 4         | 363       | 1.1       | 5       | 197       | 2.5       | 5       | 240       | 2.1       | 14       | 800       | 1.8       |
| 1999–00  | 2         | 170       | 1.2       | 1       | 186       | 0.5       | 4       | 248       | 1.6       | 7        | 604       | 1.2       |
| 2000–01  | 1         | 198       | 0.5       | 2       | 206       | 1.0       | 4       | 227       | 1.8       | 7        | 631       | 1.1       |
| 2001–02  | 2         | 202       | 1.0       | 2       | 122       | 1.6       | 1       | 258       | 0.4       | 5        | 582       | 0.9       |
| 2002–03  | 2         | 196       | 1.0       | 1       | 136       | 0.7       | 1       | 218       | 0.5       | 4        | 550       | 0.7       |
| 2003–04  | 6         | 152       | 3.9       | 1       | 157       | 0.6       | 4       | 235       | 1.7       | 11       | 544       | 2.0       |
| Total    | 22        | 1,565     | 1.4       | 15      | 1,225     | 1.2       | 22      | 1,628     | 1.4       | 59       | 4,418     | 1.3       |
This study was supported, in part, by the Tuberculosis Ultraviolet Shelter Study (TUSS).

Scott J. Bucher,*
Philip W. Brickner,*
and Richard L. Vincent*

*St. Vincent’s Hospital-Manhattan, New York, New York, USA

References

1. Rogers MA, Wright JG, Levy BD. Influenza. In: O’Connell JJ, Swain SE, Daniels CL, Allen JS, editors. The health care of homeless persons: a manual of communicable diseases and common problems in shelters and on the streets. Boston: Boston Healthcare for the Homeless Program, 2004. p. 67–71.

2. US Department of Health and Human Services. Healthy people 2010. 2nd ed. With understanding and improving health and objectives for improving health. Washington: US Government Printing Office; 2000 [cited 2006 Apr 26]. Available from http://www.healthypeople.gov/

3. Haddad MB, Wilson TW, Ijaz K, Marks SM, Moore M. Tuberculosis and homelessness in the United States, 1994–2003. JAMA. 2005;293:2762–6.

4. Shariatzadeh MR, Huang JQ, Tyrrell GJ, Johnson MM, Marrie TJ. Bacteremic pneumococcal pneumonia: a prospective study in Edmonton and neighboring municipalities. Medicine (Baltimore). 2005;84:147–61.

5. Hwang SW. Mortality among men using homeless shelters in Toronto, Ontario. JAMA. 2000;283:2152–7.

6. Hibbs JR, Benner L, Klugman L, Spencer R, Macchia I, Mellinger A, et al. Mortality in a cohort of homeless adults in Philadelphia. N Engl J Med. 1994;331:304–9.

7. Hwang SW, Orav EJ, O’Connell JJ, Lebow JM, Brennan TA. Causes of death in homeless adults in Boston. Ann Intern Med. 1997;126:625–8.

8. Kerker B, Bainbridge J, Li W, Kennedy J, Bennani Y, Agerton T, et al. The health of homeless adults in New York City: a report from the New York City Departments of Health and Mental Hygiene and Homeless Services. New York: Departments of Health and Mental Hygiene and Homeless Services; 2005

9. Centers for Disease Control and Prevention. Fact sheet: influenza (flu) [monograph on the internet]. Atlanta: The Centers; 2001 [cited 2006 Jan 25]. Available from http://www.cdc.gov/flu/weekly/pdf/flu-surveillance-overview.pdf

10. Allsup SJ, Gosney MA. Difficulties of recruitment for a randomized controlled trial involving influenza vaccination in healthy older people. Gerontontology. 2002;48:170–3.

Address for correspondence: Philip W. Brickner, Department of Community Medicine, St. Vincent’s Hospital-Manhattan, 41–51 East 11th St, 9th Floor, New York, NY 10003, USA; email: drpwb@aol.com

Human West Nile Virus Infection, Catalonia, Spain

To the Editor: West Nile virus (WNV) is a mosquito-borne flavivirus that is widespread in Africa, the Middle East, Asia, and southern Europe, where it causes outbreaks and sporadic cases of the disease. It has become an emergent disease in North America, where it was detected for the first time in 1999 and became epidemic shortly thereafter (1). Although WNV was initially considered to have a minor health effect in the Mediterranean basin, human and equine outbreaks reported in the last decade in different countries (2–5) have made WNV infections a public health concern.

The epidemiology of WNV in Europe differs from that in America and has only been associated with nonrecurrent, sporadic outbreaks. The reasons for this difference are controversial: it may be due to environmental factors, reservoirs, or even mosquito vectors. In Spain, neither equine nor human WNV cases have been reported. However, some human serosurveys that used hemagglutination inhibition suggested that WNV or closely related flaviruses circulated during the 1970s in the Ebro delta and areas in Spain (6,7). The Ebro delta, a wetland in Catalonia, in the northeast of Spain, is a stopping-off point for birds migrating between regions of Africa and Europe where different WNV vectors and reservoirs have been identified. The delta could be considered a high-risk area for WNV and other arthropodborne virus infections.

To evaluate WNV seroprevalence in the human population of the Ebro delta, a survey was conducted in 2001. After obtaining informed consent, 992 serum samples were obtained from inhabitants of the area. The population studied was representative of the whole area and was stratified by sex and age.

Anti-WNV immunoglobulin G (IgG) antibodies were determined by using an in-house indirect enzyme-linked immunosorbent assay (ELISA), as previously described (8). Results were classified as the sample absorbance/positive control absorbance ratio. Samples showing ratio values >0.2 were tested for WNV IgG and IgM by using an indirect and a μ-chain capture ELISA, respectively (Focus Technologies, Cypress, CA, USA), and an in-house microneutralization test.

For the microneutralization test, samples were tested in duplicate and assayed twice. Twofold dilutions (25 μL) of the samples (1:16–1:256 dilutions) were assayed by using 100 TCID₅₀ (50% tissue culture infectious dose) of West Nile Eg-101 reference strain in 96-well tissue culture plates with Vero cells and after 7 days of incubation at 37°C and 5% CO₂.

Thirty-eight samples showed IgG ratios >0.2 by the in-house ELISA. Of these, 12 showed WNV IgG, and 1 was positive for WNV IgM and IgG, according to the Focus assays. Two samples showed positive neutralizing activity, with titers of 32 and 256. The highest titer was shown by the sample that yielded positive levels of both IgM and IgG in the ELISA, which suggests recent WNV infection.